eBook 2026 Pharma Predictions & Trends

Global tariffs and trade tensions will continue to pressure biopharmaceutical manufacturers, driving supply chain decisions and the economics of domestic production. However, contract development and manufacturing organizations are decidedly positive about their respective outlooks for this year, having navigated geopolitical hurdles as well as the challenging funding environment in 2025.

The 2026 outlook for the outsourcing and services space is optimistic based on the biopharma industry’s funding levels, product pipeline, and research and development (R&D) spending. Life science tools companies will also benefit this year from a decidedly more positive industry outlook.

Large biopharma companies have pledged to invest hundreds of billions of dollars in U.S. infrastructure over the next few years, which has resulted in a focus on reshoring more production — a potential tailwind for the industry. This eHandbook examines these trends and explores biomanufacturing scaling and supply chain resilience — two top priorities as companies look to mitigate risks and capitalize on 2026’s growth opportunities.

Sponsored by: Greene Tweed